Quick search:
Content Ideas
| Result | Content Idea | Research |
|---|---|---|
| Result | Content Idea | Research |
| 1 | MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update |
|
| 2 | MEI Pharma |
|
| 3 | MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts |
|
| 4 | Analyst Rating: Will MEI Pharma Inc (MEIP) Stock Outperform the Market? |
|
| 5 | Do Analysts Agree on MEI Pharma Inc (MEIP) Stock's Target Price? |
|
| 6 | $2.08 Million in Sales Expected for MEI Pharma, Inc. (NASDAQ:MEIP) This Quarter |
|
| 7 | MEI Pharma (MEIP) Reports Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update |
|
| 8 | Why MEI Pharma Is Tanking 15.3% Today |
|
| 9 | MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights |
|
| 10 | MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program |
|
| 11 | MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. |
|
| 12 | MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights |
|
| 13 | MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences |
|
| 14 | Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma |
|
| 15 | MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing |
|
| 16 | Histone Deacetylase 1 Market Global Competition, Size, Business Outlook Market Dynamics 2021 Forecast to 2027 4SC AG, Acetylon Pharmaceuticals, Inc. |
|
| 17 | MEI Pharma Announces Fast Track Designation Granted by US FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma |
|
| 18 | MEI Pharma: Give It Another Chance |
|
| 19 | Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes |
|
| 20 | MEI Pharma nabs $100M upfront and weighty biobucks in upgraded Kyowa Kirin cancer drug deal |
|
| 21 | Histone Deacetylase Inhibitors Market to witness astonishing growth with Key Players : 4SC AG, Acetylon Pharmaceuticals, Celleron Therapeutics, Chroma Therapeutics, CrystalGenomics |
|
| 22 | Global Myelodysplastic syndromes (MDS) Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 – KSU | The Sentinel Newspaper |
|
| 23 | Growth Investors: Industry Analysts Just Upgraded Their MEI Pharma, Inc. (NASDAQ:MEIP) Revenue Forecasts By 25% |
|
| 24 | Earnings Release: Here's Why Analysts Cut Their MEI Pharma, Inc. (NASDAQ:MEIP) Price Target To US$9.50 |
|
| 25 | A Look At MEI Pharma's (NASDAQ:MEIP) CEO Remuneration |
|
| 26 | MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards? |
|
| 27 | MEIP SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm |
|
| 28 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – MEIP |
|
| 29 | MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm |
|
| 30 | Constellation Pharma: CPI-0610 Is Well-Differentiated In The Myelofibrosis Treatment Development Pipeline |
|
| 31 | Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway |
|
| 32 | Portnoy Law: Lawsuit Filed On Behalf of MEI Pharma, Inc. Investors |
|
| 33 | Read This Before Selling MEI Pharma, Inc. (NASDAQ:MEIP) Shares |
|
| 34 | Should You Buy MEI Pharma Inc (MEIP) Stock After it Is Up 11.74% in a Week? |
|
| 35 | Have Insiders Been Buying MEI Pharma, Inc. (NASDAQ:MEIP) Shares This Year? |
|
| 36 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. |
|
| 37 | MEI Pharma Inc (MEIP) Up 4.09% in Premarket Trading |
|
| 38 | Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. (MEIP) |
|
| 39 | ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of the Important Deadline in Securities Class Action – MEIP |
|
| 40 | MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Trimmed Their Revenue Forecasts By 0.9% |
|
| 41 | What Is The Ownership Structure Like For MEI Pharma, Inc. (NASDAQ:MEIP)? |
|
| 42 | Pomerantz Law Firm Announces the Filing of a Class Action against MEI Pharma, Inc. and Certain Officers |
|
| 43 | MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program |
|
| 44 | Analysts Are Upgrading MEI Pharma, Inc. (NASDAQ:MEIP) After Its Latest Results |
|
| 45 | What Can We Learn About MEI Pharma's (NASDAQ:MEIP) CEO Compensation? |
|
| 46 | MEI Pharma Set To Explode With Announcement Of Lucrative Partnership |
|
| 47 | DEADLINE ALERT: Bragar Eagel & Squire, PC Reminds Investors That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm |
|
| 48 | BRIEF-Helsinn Group And Mei Pharma Discontinue The Phase 3 Study With Pracinostat In Aml After Completing Interim Analysis |
|
| 49 | MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Are Pretty Bullish On The Stock After Recent Results |
|
| 50 | Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against MEI Pharma, Cabot Oil & Gas, Kodak, and Genius Brands and Encourages Investors to Contact the Firm |
|
| 51 | Why MEI Pharma's Stock Is Trading Higher Today |
|
| 52 | How Many MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Institutions Own? |
|
| 53 | How Should Investors React To MEI Pharma, Inc.'s (NASDAQ:MEIP) CEO Pay? |
|
| 54 | MEIP EQUITY NOTICE: ROSEN, A NATIONAL INVESTOR LAW FIRM, Encourages MEI Pharma, Inc. Investors with Losses to Contact Firm Before Important Deadline in Securities Class Action – MEIP |
|
| 55 | The MEI Pharma (NASDAQ:MEIP) Share Price Has Gained 41% And Shareholders Are Hoping For More |
|
| 56 | Earnings Update: MEI Pharma, Inc. (NASDAQ:MEIP) Just Reported And Analysts Are Trimming Their Forecasts |
|
| 57 | Could Mei Pharma Inc (NAQ:MEIP) be a turtle trade? |
|
| 58 | Kyowa Kirin invests in MEI Pharma's blood-cancer drug |
|
| 59 | How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry |
|
| 60 | MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies |
|
| 61 | BRIEF-Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study |
|
| 62 | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc. – MEIP |
|
| 63 | BRIEF-Helsinn And MEI Pharma Announce Updated Clinical Data From Phase 2 Study Evaluating Pracinostat In Combination With Azacitidine |
|
| 64 | Will MEI Pharma Inc (MEIP) Beat the Rest of the Stocks in the Healthcare Sector? |
|
| 65 | We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely |
|
| 66 | Histone Deacetylase 2 Market To Observe Exponential Growth By 2020-2027 | UpMarketResearch – NeighborWebSJ |
|
| 67 | MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML) |
|
| 68 | The end of the road beckons for pracinostat |
|
| 69 | COVAXX, Aurobindo sign Covid-19 vaccine development deal |
|
| 70 | San Diego Life Sciences Roundup: MEI Pharma, Turning Point, & More |
|
| 71 | Is MEIP A Good Stock To Buy Now? |
|
| 72 | How Will Global Histone Deacetylase (Hdac) Inhibitors Market React from 2021 Onwards? – Murphy's Hockey Law |
|
| 73 | MEI Pharma: Best-In-Class P13K Delta Inhibitor Makes Significant Progress In The Clinic |
|
| 74 | Lifshitz Law Firm, PC Announces Investigation of Cognizant Technology Solutions Corporation, Honeywell International Inc., MEI Pharma, Inc., Nikola Corporation, The Chemours Company and YayYo, Inc. |
|
| 75 | MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies |
|
| 76 | Aurobindo and COVAXX sign deal to develop Covid-19 vaccine UB-612 |
|
| 77 | MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan |
|
| 78 | Covid-19 Impact on Histone Deacetylase 2 Market (2020-2026) | Potential growth, attractive valuation make it is a long-term investment | Top Players: 4SC AG, Acetylon Pharmaceuticals Inc., Chipscreen Biosciences Ltd, Curis Inc., GlaxoSmithKline Plc |
|
| 79 | MEI Pharma licenses ME-401 to Kyowa Hakko Kirin in Japan |
|
| 80 | Meridian Bioscience : Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience? |
|
| 81 | MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor |
|
| 82 | COVAXX CEO Works to Redefine the Idea of a Vaccine |
|
| 83 | MEI Pharma Announces Closing of Public Offering of Common Stock |
|
| 84 | MEI Pharma Announces Topline Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug Candidate ME-344 |
|
| 85 | Imagine Owning MEI Pharma (NASDAQ:MEIP) And Trying To Stomach The 78% Share Price Drop |
|
| 86 | Do Directors Own MEI Pharma, Inc. (NASDAQ:MEIP) Shares? |
|
| 87 | Nov 18, 2020 |
|
| 88 | UB-612 COVID-19 Vaccine |
|
| 89 | After Strikeout, San Diego's MEI Pharma Looks to Rebuild Confidence |
|
| 90 | No strings attached: COVID-19 pandemic raises profile of non-dilutive funding for life science companies |
|
| 91 | Asco 2020 movers – cell therapy companies dominate the risers |
|
| 92 | FDA Grants Fast Track Designation to PI3K Inhibitor ME-401 for Patients with FL |
|
| 93 | Non-Hodgkin's Lymphoma (NHL) Therapeutics Clinical Trial Analysis Report 2020 |
|
| 94 | Another endorsement for PI3K delta, this time in oncology |
|
| 95 | BRIEF-MEI Pharma Announces $75 Mln Private Placement |
|
| 96 | Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances |
|
| 97 | MEI Pharma Reports Second Quarter Fiscal Year 2017 Results |
|
| 98 | Presage Bio Licenses Anti-Cancer Drug to San Diego's MEI Pharma |
|
| 99 | Cue Biopharma Welcomes Tamar Howson to its Board of Directors |
|
| 100 | Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares |
|